Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 60, Issue 6, 2009, Pages 1785-1796

  Yao, Yihong ^a,b   Richman, Laura ^a   Higgs, Brandon W ^a   Morehouse, Christopher A ^a   De Los Reyes, Melissa ^a   Brohawn, Philip ^a   Zhang, Jianliang ^a   White, Barbara ^a   Coyle, Anthony J ^a   Kiener, Peter A ^a   Jallal, Bahija ^a  

^a MEDIMMUNE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BETA INTERFERON; BIOLOGICAL MARKER; CD4 ANTIGEN; CD83 ANTIGEN; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON ALPHA INDUCIBLE PROTEIN; INTERFERON BETA INDUCIBLE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY INTERFERON ALPHA; PROTEIN BDCA2; PROTEIN HERC 5; PROTEIN ISG 15; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; GENE; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INTERFERON ALPHA INDUCIBLE GENE; INTERFERON BETA INDUCIBLE GENE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-1BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; SKIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66449097622     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24557     Document Type: Article

References (28)

1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999;42:1785-1796
2. Vasoo S, Hughes GR. Theory, targets and therapy in systemic lupus erythematosus. Lupus 2005;14:181-188 (Pubitemid 40445580)
3. Smith PL, Lombardi G, Foster GR. Type I interferons and the innate immune response: more than just antiviral cytokines. Mol Immunol 2005;42:869-877 (Pubitemid 40489010)
4. Conlon KC, Urba WJ, Smith JW II, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving α-interferon therapy. Cancer 1990;65:2237-2242 (Pubitemid 20164829)
5. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47. (Pubitemid 26037204)
6. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-α. Br J Dermatol 1991;125:463-465
7. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-291 (Pubitemid 26323465)
8. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005;52:1491-1503 (Pubitemid 40663941)
9. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-2615 (Pubitemid 36297546)
10. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-723 (Pubitemid 36350866)
11. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003;4:177-186 (Pubitemid 38967595)
12. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006;54:1906-1916 (Pubitemid 43877940)
13. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-671 (Pubitemid 32011791)
14. Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-1697 (Pubitemid 41667141)
15. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979;301:5-8. (Pubitemid 9226519)
16. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006;18:676-682 (Pubitemid 44635182)
17. Wallace DJ, Petri M, Olsen N, Kirou K, Dennis G, Yao Y, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematous [abstract]. Arthritis Rheum 2007;56 Suppl 9:S526-7.
18. Adjei AA. Incorporating biomarkers into early phase clinical trials [abstract]. Ann Oncol 2006;17 Suppl 3:iii21.
19. Yao Y, Higgs BW, Morehouse C, de los Reyes M, Trigona W, Brohawn P, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics, 2009. URL: http://www.sage-hindawi.com/getarticle.aspx? doi=10.4061/2009/374312.
20. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008;3:e2737.
21. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007;27:461-466 (Pubitemid 47319257)
22. Fiehn C, Wermann M, Pezzutto A, Hufner M, Heilig B. Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy. Z Rheumatol 1992;51:121-6. In German.
23. Borodin AG, Baranov AA, Kliukvina NG, Abaitova NE, Nasonov EL. Clinical and pathogenic significance of tumor necrosis factor-α in systemic lupus erythematosus. Ter Arkh 2002;74:32-5. In Russian.
24. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-αin autoimmune diseases. Proc Natl Acad Sci U S A 2005;102:3372-3377 (Pubitemid 40328052)
25. Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007;46:1083-1086 (Pubitemid 47050608)
26. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-3486 (Pubitemid 37531913)
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277 (Pubitemid 13221242)
28. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.